Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 1
Aptose Reports First Quarter 2026 Results
05:00pm, Wednesday, 13'th May 2026
SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a
Aptose Biosciences (TSE:APS) Stock Passes Above 50-Day Moving Average – Time to Sell?
03:13am, Tuesday, 31'st Mar 2026
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s share price passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of C$2.21 and t
Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?
03:32am, Saturday, 24'th Jan 2026
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$2.19 and
Aptose's Tuspetinib Triple Drug Therapy Featured at 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Population
Aptose Biosciences (TSE:APS) Shares Pass Above Fifty Day Moving Average – Should You Sell?
04:32am, Wednesday, 03'rd Dec 2025
Aptose Biosciences Inc. (TSE: APS - Get Free Report) (NASDAQ: APTO) crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$1.89 and traded
Aptose Announces Auditor Not Standing for Re-Appointment
05:00pm, Wednesday, 23'rd Apr 2025
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TU
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
07:30am, Wednesday, 23'rd Apr 2025
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (T
Aptose Reports Year End 2024 Results and Corporate Highlights
08:01am, Friday, 28'th Mar 2025
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversi
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
07:30am, Monday, 17'th Mar 2025
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing t
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
01:11pm, Thursday, 20'th Feb 2025
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax a
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
Aptose Announces Reverse Share Split
04:30pm, Tuesday, 18'th Feb 2025
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing th
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
04:30pm, Thursday, 13'th Feb 2025
SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing t
TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows fav
